Patrick Moore, MD
Family Medicine · Lafayette, LANPI 1982604419
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 423 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$980
- Amgen$813
- Lilly USA, LLC$665
- Boehringer Ingelheim$508
- Novartis$379
- plus $3K from 31 others
Across 4 payments — averaging $6321.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$25K
What the payments were for
- Food & beverage$7,094100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $1,144 |
| AstraZeneca | 55 | $980 |
| Amgen(2 entities) | 53 | $813 |
| Lilly USA, LLC | 41 | $665 |
| Boehringer Ingelheim | 30 | $508 |
| Novartis | 27 | $379 |
| Novo Nordisk | 25 | $367 |
| Amarin Pharma, Inc. | 24 | $324 |
| AbbVie(2 entities) | 17 | $262 |
| Esperion Therapeutics, Inc. | 15 | $256 |
| Pfizer | 8 | $155 |
| Zynex Medical, Inc. | 1 | $140 |
| Agepha Pharma FZ LLC | 1 | $129 |
| Johnson & Johnson | 8 | $124 |
| Scpharmaceuticals Inc. | 6 | $111 |
| Corcept Therapeutics | 5 | $109 |
| Merck | 7 | $92 |
| Atricure, Inc. | 2 | $87 |
| Philips North America LLC | 1 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Dexcom, Inc. | 3 | $52 |
| Global Blood Therapeutics, Inc. | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Getinge USA Sales, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,120 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 378 | $536,809 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 192 | $221,694 |
| JardianceEmpagliflozin | 174 | $206,812 |
| TrulicityDulaglutide | 122 | $197,221 |
| TradjentaLinagliptin | 151 | $165,498 |
| VascepaIcosapent Ethyl | 192 | $136,347 |
| LinzessLinaclotide | 85 | $83,904 |
| XareltoRivaroxaban | 59 | $77,001 |
| FuroscixFurosemide | 11 | $76,454 |
| FarxigaDapagliflozin Propanediol | 75 | $75,765 |
| OzempicSemaglutide | 60 | $75,298 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $43,005 |
| Repatha SyringeEvolocumab | 50 | $30,327 |
| Repatha SureclickEvolocumab | 35 | $23,611 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 17 | $23,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $665 | $734,030500 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $508 | $395,842342 claims |
| GSKTrelegy Ellipta | $1,144 | $221,694192 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $980 | $128,635139 claims |
| AbbVieLinzess, Armour Thyroid | $262 | $87,955130 claims |
| Johnson & JohnsonXarelto | $124 | $77,00159 claims |
| Scpharmaceuticals Inc.Furoscix | $111 | $76,45411 claims |
| Novo NordiskOzempic | $367 | $75,29860 claims |
| NovartisEntresto | $379 | $16,99315 claims |
| PfizerEliquis | $155 | $11,67813 claims |
| Esperion Therapeutics, Inc.Nexlizet | $256 | $10,78411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lafayette
- Geoffrey MireLafayette$13K
- Darrin MenardLafayette$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.